Ginkgo - Natural Standard - Therapeutic Research Center
... mixed dementias. Studies lasting from 3 months to a year show that ginkgo leaf extract can stabilize or improve some measures of cognitive function and social functioning in patients with multiple types of dementia (1514, 1515, 2665, 2666, 6222, 6223, 6224, 6225, 6490, 11981, 16636) (17191, 17717, 8 ...
... mixed dementias. Studies lasting from 3 months to a year show that ginkgo leaf extract can stabilize or improve some measures of cognitive function and social functioning in patients with multiple types of dementia (1514, 1515, 2665, 2666, 6222, 6223, 6224, 6225, 6490, 11981, 16636) (17191, 17717, 8 ...
Signs and Symptoms Guide.
... intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine if there is such inadvertent administration. • Do not inject into buttock. Injection into the buttock may ...
... intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine if there is such inadvertent administration. • Do not inject into buttock. Injection into the buttock may ...
HIV/AIDS Guidelines - Infectious Diseases Society of America
... association for potential conflict of interest and determine the appropriate action: disqualification from the panel, disqualification/recusal from topic review and discussion; no disqualification needed. A conflict of interest is defined as any direct financial interest related to a product address ...
... association for potential conflict of interest and determine the appropriate action: disqualification from the panel, disqualification/recusal from topic review and discussion; no disqualification needed. A conflict of interest is defined as any direct financial interest related to a product address ...
Natural Medicines - Professional - Natural Standard
... or mixed dementias. Studies lasting from 3 months to one year show that ginkgo leaf extract can stabilize or improve some measures of cognitive function and social functioning in patients with multiple types of dementia (1514, 1515, 2665, 2666, ...
... or mixed dementias. Studies lasting from 3 months to one year show that ginkgo leaf extract can stabilize or improve some measures of cognitive function and social functioning in patients with multiple types of dementia (1514, 1515, 2665, 2666, ...
COPYRIGHTED MATERIAL- DO NOT ALTER OR REPRODUCE
... Management of asthma exacerbations in primary care (adults, adolescents, children 6–11 years) ................ 78 Management of asthma exacerbations in acute care facility, e.g. emergency department .............................. 81 Discharge management after hospital or emergency department care fo ...
... Management of asthma exacerbations in primary care (adults, adolescents, children 6–11 years) ................ 78 Management of asthma exacerbations in acute care facility, e.g. emergency department .............................. 81 Discharge management after hospital or emergency department care fo ...
Theophylline
... studies, reviews, metaanalyses and Cochrane reviews. Especially the pharmacokinetic studies are valuable and demonstrate important aspects of the developmental changes in the pharmacokinetic parameters during the various stages in childhood, whereas the clinical studies add less to the knowledge of ...
... studies, reviews, metaanalyses and Cochrane reviews. Especially the pharmacokinetic studies are valuable and demonstrate important aspects of the developmental changes in the pharmacokinetic parameters during the various stages in childhood, whereas the clinical studies add less to the knowledge of ...
Global Strategy for Asthma Management and Prevention (2016
... This document should be cited as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org ...
... This document should be cited as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org ...
MDF Toolkit - Myotonic Dystrophy Foundation
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
International ERS/ATS guidelines on definition, evaluation and
... The purpose of this document is to revise the definition of severe asthma, discuss the possible phenotypes and provide guidance about the management of patients with severe asthma. The target audience of these guidelines is specialists in respiratory medicine and allergy managing adults and children ...
... The purpose of this document is to revise the definition of severe asthma, discuss the possible phenotypes and provide guidance about the management of patients with severe asthma. The target audience of these guidelines is specialists in respiratory medicine and allergy managing adults and children ...
Humira : EPAR - EMA
... lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. With the current knowledge, a possible risk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antag ...
... lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. With the current knowledge, a possible risk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antag ...
March 21-25, 2014 - American Academy of Dermatology
... The association between bullous pemphigoid (BP) and multiple neurologic diseases has been well-documented, but population-based studies from the United States are lacking. BP antigen 1 has similar isoforms in neuronal and cutaneous tissues, which is one possible link to explain this association. How ...
... The association between bullous pemphigoid (BP) and multiple neurologic diseases has been well-documented, but population-based studies from the United States are lacking. BP antigen 1 has similar isoforms in neuronal and cutaneous tissues, which is one possible link to explain this association. How ...
MYOTONIC DYSTROPHY FOUNDATION Toolkit
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
Global Report on Psoriasis - World Health Organization
... What is psoriasis? Psoriasis is a chronic, noncommunicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact on patients’ quality of life (QoL). It can occur at any age, and is most common in the age group 50–69 (1). The reported prevalence of psor ...
... What is psoriasis? Psoriasis is a chronic, noncommunicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact on patients’ quality of life (QoL). It can occur at any age, and is most common in the age group 50–69 (1). The reported prevalence of psor ...
Dystonia: A Guide to Good Practice for Health and Social Care Professionals
... the body into abnormal movements or postures. Dystonia can affect speech, sight and mobility. There are thought to be over 70,000 adults and children in the UK who have some form of dystonia. At present there is no cure, although there are treatments which can help to alleviate symptoms. As a health ...
... the body into abnormal movements or postures. Dystonia can affect speech, sight and mobility. There are thought to be over 70,000 adults and children in the UK who have some form of dystonia. At present there is no cure, although there are treatments which can help to alleviate symptoms. As a health ...
COPYRIGHTED MATERIAL - DO NOT ALTER OR REPRODUCE
... updated annually since 2002, and publications based on the GINA reports have been translated into many languages. In 2001, GINA initiated an annual World Asthma Day, raising awareness about the burden of asthma, and becoming a focus for local and national activities to educate families and health ca ...
... updated annually since 2002, and publications based on the GINA reports have been translated into many languages. In 2001, GINA initiated an annual World Asthma Day, raising awareness about the burden of asthma, and becoming a focus for local and national activities to educate families and health ca ...
COPYRIGHTED MATERIAL - DO NOT ALTER OR REPRODUCE
... updated annually since 2002, and publications based on the GINA reports have been translated into many languages. In 2001, GINA initiated an annual World Asthma Day, raising awareness about the burden of asthma, and becoming a focus for local and national activities to educate families and health ca ...
... updated annually since 2002, and publications based on the GINA reports have been translated into many languages. In 2001, GINA initiated an annual World Asthma Day, raising awareness about the burden of asthma, and becoming a focus for local and national activities to educate families and health ca ...
The diagnosis and management of rhinitis
... AstraZeneca. M. S. Dykewicz has consulting arrangements with AstraZeneca, GlaxoSmithKline, McNeil, Medpointe/Meda, Merck, Novartis/Genentech, ScheringPlough, and Teva; has received research support from AstraZeneca, GlaxoSmithKline, Novartis/Genentech, and Schering-Plough; and is on the speakers’ bu ...
... AstraZeneca. M. S. Dykewicz has consulting arrangements with AstraZeneca, GlaxoSmithKline, McNeil, Medpointe/Meda, Merck, Novartis/Genentech, ScheringPlough, and Teva; has received research support from AstraZeneca, GlaxoSmithKline, Novartis/Genentech, and Schering-Plough; and is on the speakers’ bu ...
MYOTONIC DYSTROPHY FOUNDATION Toolkit
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
... partners, and those in regulatory bodies. To conquer this disease, we will need, as many have described over the past few days, to work together as a team, and together with patients. DM families – many people go through life not finding that thing that drives them, that thing they live, or die, for ...
Treatments for Atopic Eczema
... he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, si ...
... he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, si ...
dystonia update
... Spasmodic Torticollis (Cervical Dystonia) Cervical dystonia is the most common form of focal dystonia. More frequent in women, it can occur at any age but more frequently around 5012. It involves involuntary contractions of the neck muscles causing a variety of abnormal movements and postures of the ...
... Spasmodic Torticollis (Cervical Dystonia) Cervical dystonia is the most common form of focal dystonia. More frequent in women, it can occur at any age but more frequently around 5012. It involves involuntary contractions of the neck muscles causing a variety of abnormal movements and postures of the ...
Prescribing Information and Medication Guide
... The recommended starting dose when converting from other opioids to fentanyl transdermal system is intended to minimize the potential for overdosing patients with the first dose. Discontinue all other around-the-clock opioid drugs when fentanyl transdermal system therapy is initiated. While there ar ...
... The recommended starting dose when converting from other opioids to fentanyl transdermal system is intended to minimize the potential for overdosing patients with the first dose. Discontinue all other around-the-clock opioid drugs when fentanyl transdermal system therapy is initiated. While there ar ...
Intravitreal triamcinolone acetonide for treatment of intraocular
... Intravitreal triamcinolone acetonide (IVTA) has increasingly been applied as treatment for various intraocular neovascular and oedematous diseases. Comparing the various diseases with respect to effect and side-effects of the treatment, the best response in terms of gain in visual acuity (VA) has be ...
... Intravitreal triamcinolone acetonide (IVTA) has increasingly been applied as treatment for various intraocular neovascular and oedematous diseases. Comparing the various diseases with respect to effect and side-effects of the treatment, the best response in terms of gain in visual acuity (VA) has be ...
Priapism - European Association of Urology
... metabolic environment, progressively leading to hypoxia, hypercapnia, and acidosis. Ischaemic priapism beyond 4 hours is considered a compartment syndrome, characterised by supraphysiological pressure within the closed space of the corpora cavernosa, which severely compromises cavernous circulation. ...
... metabolic environment, progressively leading to hypoxia, hypercapnia, and acidosis. Ischaemic priapism beyond 4 hours is considered a compartment syndrome, characterised by supraphysiological pressure within the closed space of the corpora cavernosa, which severely compromises cavernous circulation. ...
New Perspectives on Dystonia
... Spasmodic Torticollis (Cervical Dystonia) Cervical dystonia is the most common form of focal dystonia. More frequent in women, it can occur at any age but more frequently around 5012. It involves involuntary contractions of the neck muscles causing a variety of abnormal movements and postures of the ...
... Spasmodic Torticollis (Cervical Dystonia) Cervical dystonia is the most common form of focal dystonia. More frequent in women, it can occur at any age but more frequently around 5012. It involves involuntary contractions of the neck muscles causing a variety of abnormal movements and postures of the ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.